)
We move precision oncology forward.
About IndivumedThe target ID company
Indivumed is a biotech company focused on precision oncology. We discover novel targets for the development of precision cancer therapeutics.
:format(webp))
“Together, we envision a world where precision therapy offers a cure for every cancer patient.”
Our MissionCancer is as unique as the humans it affects. The same should apply to the therapies.
We strive for a future in which every cancer patient can benefit from precise therapeutic treatments. Highly individualized cancer therapy is the vision on which our company was founded and the origin of the “Indivu” in our name. To achieve this goal, we dedicate our skills and knowledge in cancer research to the discovery and development of novel therapeutics. With more than twenty years of experience and a truly unique resource, we are committed to transforming oncology and bringing the best possible therapies to patients.
Explore the highlights of our journey.
Change is part of our history. For close to 25 years, Indivumed has been continuously evolving, building valuable relationships around the world, and earning an excellent reputation in the scientific community. We are always on the lookout for innovative partnerships and new solutions to help us realize our vision.
)
2025 R&D in focus
Going forward, we continue to dedicate our full attention to the data-driven identification and validation of therapeutically novel targets. With a growing number of promising candidates in our pipeline, we are firmly on track to accelerate the development of first-in-class cancer therapeutics.
)
2023 Shifting the paradigm
After five years of running two distinct business units in parallel, we make the decision to reinvent ourselves. The separation and sale of our CRO service division marks a major milestone in our evolution, transforming Indivumed into a dedicated and focused biotech R&D company.
)
2018 We have a type
Supported by the European Fund for Strategic Investments (EFSI), the European Investment Bank (EIB) provides us with a EUR 40 million loan. Twelve months later, we launch IndivuType – a world-first multi-omics cancer database and cornerstone of our R&D activities to advance precision oncology.
)
2017 Networking
Our network of clinical partners reaches an important milestone: as the first partner in Asia, the Indian Institute of Technology in Chennai joins us in advancing precision oncology, closely followed in 2018 by A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore. Today, the Indivumed Global Clinical Network includes some of the most prestigious hospitals, clinics, and oncology institutions in Europe, North America, and Asia.
)
2008 Drawing blood
Together with scientists led by Professor Bert Vogelstein from Johns Hopkins University, we found Inostics GmbH to elaborate a new system of cancer gene diagnostics from blood. The team is later recognized by the AACR for its pioneering work inventing the field of “liquid biopsy” testing by detecting cancer mutations as biomarkers – a disruptive technological advancement that defined a new field in oncology.
)
2005 The visionary
The jury of Deutscher Gründerpreis (German Founders Award) honors Hartmut Juhl with the award in the “Visionary” category. The prestigious award celebrates outstanding entrepreneurial achievements and recognizes personalities who turn visions into ventures.
)
2002 Indivu… what?
As early as September 2001, Prof. Dr. Hartmut Juhl starts Indivumed GmbH as CEO. Despite – or perhaps because of – the name, which might be difficult to pronounce at first, investors are quickly found. Operations begin April 5, 2002, with five employees. Soon after, Indivumed is awarded the Hamburger Gründerpreis for best start-up company in Hamburg.
Mangement boardMeet the team that leads our mission.
Our leadership team unites a passion for discovery with a commitment to excellence. With diverse skill sets and a bold vision, they are the architects of our unique position.
)
Prof. Dr. Hartmut Juhl
is a surgical oncologist, entrepreneur, and researcher to the core. His vision of improving cancer patient care and his idea to standardize the collection of tumor samples led to the foundation of Indivumed in 2002.
)
Prof. Dr. Anton Wellstein, MD, PhD
is a renowned pharmacology professor at the Lombardi Comprehensive Cancer Center, Georgetown University. His impressive track record in oncology and pharmacology includes more than 200 peer-reviewed publications and many prestigious awards.
)
Dr. Matthias Evers
is a biochemist and life sciences executive with a 20-year-plus track record in pharmaceuticals and biotechnology. He brings extensive strategic, operational, technology, and business development expertise to the team.
)
Nils John Schumacher
is a lawyer, business economist, and mediator by training with more than 25 years of leadership experience in internationally operating IT and data-driven companies. He brings expertise in international law, HR, and corporate finance to the Indivumed team.
)
Prof. Dr. Stephan Schüller
With more than three decades of experience as a business executive, financial leader, professor, and board member for several financial institutions, Prof. Schüller brings highly valuable knowledge and perspectives to Indivumed.
)
)
)
)
)
)